nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

21.06.2017 | Review Article

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)

verfasst von: İsa Burak Güney

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third cause of cancer death globally with most deaths occurring within 1 year of diagnosis. HCC is the sixth most common malignancy worldwide [1‐3]. Transplantation and resection remain the only potentially curative options [4]. Locoregional therapies such as chemoembolization (TACE) and radiofrequency ablation have an established palliative role in select patients [5‐9]. Targeted molecular therapies now have a recognized role, with sorafenib demonstrating improved survival in patients with advanced HCC [10, 11]. …

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRef

Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.CrossRef

El-Serag HB. Current concepts: hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRef

European Association For The Study Of The Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRef

Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572–86.CrossRef

Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234:954–60.CrossRef

Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004;10:449–55.CrossRef

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRef

10.

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.CrossRef

11.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.CrossRef

12.

Sirtex Medical. Package Insert for SIR-Spheres ® microspheres (Yttrium-90 microspheres). http://www.sirtex.com; http://sirtex.com/files/US20Package20Insert1.pdf

13.

MDS Nordion. Package Insert for TheraSphereYttrium-90 glass microspheres. http://www.nordion.com/therasphere/physicians-packageinsert/package-insert-us.pdf

14.

Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol. 2011;34:337–41. doi:10.1097/COC.0b013e3181ec61bb.CrossRefPubMed

15.

Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23. doi:10.1016/j.ijrobp.2006.11.060.CrossRefPubMed

16.

Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors. Cancer. 2008;112(7):1538–46.CrossRef

17.

Delbeke D, Martin WH. Positron emission tomography in oncology. Radiol Clin N Am. 2001;39:883–917.CrossRef

18.

Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–6.CrossRef

19.

Soydal C, Alkan A, Ozkan E, Demirkazık A, Kucuk NO. Ga-68 PSMA accumulation in hepatocellular carcinoma. Clin Oncol. 2016;1:1091.

Titel: HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)
verfasst von: İsa Burak Güney
Publikationsdatum: 21.06.2017
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 3/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9973-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Molecular Pathogenesis of Liver Cancer

New Paradigm: Adaptive Approach

Is That Possible to Stop or Cease the NASH to Turn into HCC?

Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors

Liver Transplantation for Hepatocellular Carcinoma: “Experience of Memorial Sisli Hospital”

Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie